Replies to post #57423 on GoodFellas Big Board Catalyst and Chart Plays

[unspokenvoice]

Tivantinib is their lead product, according to their website

Lead Product

ArQule has advanced into Phase 3 clinical development with its lead product, tivantinib (ARQ 197), an orally available, small molecule that inhibits the c-Met receptor tyrosine kinase without competing with ATP for its binding to this kinase.

Looks like they have 5 drugs in their pipeline

http://www.arqule.com/res/pip/